MX2019002284A - Sistemas de deposito que comprenden acetato de glatiramer. - Google Patents

Sistemas de deposito que comprenden acetato de glatiramer.

Info

Publication number
MX2019002284A
MX2019002284A MX2019002284A MX2019002284A MX2019002284A MX 2019002284 A MX2019002284 A MX 2019002284A MX 2019002284 A MX2019002284 A MX 2019002284A MX 2019002284 A MX2019002284 A MX 2019002284A MX 2019002284 A MX2019002284 A MX 2019002284A
Authority
MX
Mexico
Prior art keywords
glatiramer acetate
depot systems
depot
systems
intramuscularly
Prior art date
Application number
MX2019002284A
Other languages
English (en)
Inventor
Marom Ehud
Rubnov Shai
Bleich Kimelman Nadav
Danon Uri
Original Assignee
Mapi Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mapi Pharma Ltd filed Critical Mapi Pharma Ltd
Publication of MX2019002284A publication Critical patent/MX2019002284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Epoxy Resins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Chemical Vapour Deposition (AREA)

Abstract

La presente invención proporciona composiciones y métodos de uso de los mismos para tratar o mejorar la esclerosis múltiple (MS) mediante la administración de una formulación de depósito que comprende 40 mg de acetato de glatiramer por vía intramuscular al paciente con MS.
MX2019002284A 2016-08-31 2017-08-09 Sistemas de deposito que comprenden acetato de glatiramer. MX2019002284A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662381598P 2016-08-31 2016-08-31
PCT/IL2017/050882 WO2018042415A1 (en) 2016-08-31 2017-08-09 Depot systems comprising glatiramer acetate

Publications (1)

Publication Number Publication Date
MX2019002284A true MX2019002284A (es) 2019-09-04

Family

ID=61300274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002284A MX2019002284A (es) 2016-08-31 2017-08-09 Sistemas de deposito que comprenden acetato de glatiramer.

Country Status (20)

Country Link
US (1) US20210283209A1 (es)
EP (2) EP4252849A3 (es)
JP (1) JP7193448B2 (es)
CN (1) CN109982712A (es)
AU (1) AU2017319728A1 (es)
BR (1) BR112019003594A2 (es)
CA (1) CA3035147A1 (es)
DK (1) DK3506921T3 (es)
ES (1) ES2952044T3 (es)
FI (1) FI3506921T3 (es)
HR (1) HRP20230738T1 (es)
HU (1) HUE062393T2 (es)
IL (2) IL301455B2 (es)
LT (1) LT3506921T (es)
MX (1) MX2019002284A (es)
PL (1) PL3506921T3 (es)
PT (1) PT3506921T (es)
RS (1) RS64445B1 (es)
SI (1) SI3506921T1 (es)
WO (1) WO2018042415A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3035149A1 (en) 2016-08-28 2018-03-08 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
WO2023170493A1 (en) * 2022-03-07 2023-09-14 Hadidi Naghmeh Drug delivery using a parenteral pharmaceutical composition
WO2023175598A1 (en) * 2022-03-17 2023-09-21 Mapi Pharma Ltd. Depot systems comprising cariprazine or salts thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5800808A (en) 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
KR20170123354A (ko) 2009-08-20 2017-11-07 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 글라티라머 아세테이트를 포함하는 약제
CN107184954A (zh) * 2010-01-04 2017-09-22 Mapi医药公司 包含格拉默或其药用盐的储药系统
EP2605797A2 (en) * 2010-08-20 2013-06-26 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
PL2529757T3 (pl) * 2011-05-31 2014-04-30 Farm Rovi Lab Sa Formulacja implantu zawierającego paliperydon
CN103169670B (zh) * 2013-03-22 2016-07-06 深圳翰宇药业股份有限公司 一种醋酸格拉替雷微球及其制备方法
US20210220428A1 (en) * 2016-06-30 2021-07-22 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
CA3035149A1 (en) * 2016-08-28 2018-03-08 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate

Also Published As

Publication number Publication date
HUE062393T2 (hu) 2023-11-28
IL301455B2 (en) 2024-04-01
IL264914B1 (en) 2023-04-01
AU2017319728A1 (en) 2019-02-07
EP3506921A1 (en) 2019-07-10
IL301455A (en) 2023-05-01
EP3506921B1 (en) 2023-05-17
ES2952044T3 (es) 2023-10-26
IL264914B2 (en) 2023-08-01
US20210283209A1 (en) 2021-09-16
JP2019530648A (ja) 2019-10-24
EP4252849A2 (en) 2023-10-04
EP4252849A3 (en) 2023-11-01
PL3506921T3 (pl) 2023-08-21
PT3506921T (pt) 2023-08-07
CA3035147A1 (en) 2018-03-08
BR112019003594A2 (pt) 2019-05-21
LT3506921T (lt) 2023-08-10
RS64445B1 (sr) 2023-09-29
CN109982712A (zh) 2019-07-05
IL264914A (es) 2019-04-30
IL301455B1 (en) 2023-12-01
HRP20230738T1 (hr) 2023-10-27
EP3506921A4 (en) 2020-05-06
FI3506921T3 (fi) 2023-07-21
DK3506921T3 (da) 2023-07-31
WO2018042415A1 (en) 2018-03-08
JP7193448B2 (ja) 2022-12-20
SI3506921T1 (sl) 2023-10-30

Similar Documents

Publication Publication Date Title
MX2019002284A (es) Sistemas de deposito que comprenden acetato de glatiramer.
PH12020500500A1 (en) Pyrazolopyrimidinone compounds and uses thereof
JOP20190146A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
SG10201907164SA (en) Rna containing composition for treatment of tumor diseases
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
MX2020013557A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y métodos de uso del mismo.
WO2019006005A3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
MX2019000346A (es) Metodos y composiciones para el tratamiento del cancer.
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2019012522A (es) Compuestos y metodos terapeuticos.
PH12019501820A1 (en) Pharmaceutical compositions for combination therapy
MX2021000314A (es) Formulaciones reductoras de tumores y metodos de uso de las mismas.
MX2019010174A (es) Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
PH12020550549A1 (en) Compositions for preventing or treating lupus
MX2017003949A (es) Derivados peptidicos novedosos y sus usos.